Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Copyright policy )Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
In two recent studies, the HIF2α antagonist, PT2399, decreased HIF2α-dependent transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials.
- Center for Cancer Research United States
- National Cancer Institute United States
Basic Helix-Loop-Helix Proteins, Mice, Nude, Kidney Neoplasms, Mice, Indans, Animals, Humans, Endothelial PAS Domain-Containing Protein 1, Molecular Targeted Therapy, Sulfones, Carcinoma, Renal Cell
Basic Helix-Loop-Helix Proteins, Mice, Nude, Kidney Neoplasms, Mice, Indans, Animals, Humans, Endothelial PAS Domain-Containing Protein 1, Molecular Targeted Therapy, Sulfones, Carcinoma, Renal Cell
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).26 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!